It is a human monoclonal IgG1 antibody against PD‐L1.128 It is the first PD‐L1 inhibitor to receive FDA approval for metastatic NSCLC patients who have received front line chemotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.